Literature DB >> 11241312

DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.

S Romain1, P O Bendahl, O Guirou, P Malmström, P M Martin, M Fernö.   

Abstract

S-phase fraction (SPF) is a reference for cell-kinetic analysis. In this study, the links between SPF and the essential enzymes participating in the pyrimidine synthesis were investigated in breast cancer and their relationships with the natural history of the disease were compared. We measured thymidine kinase (TK) for salvage synthesis, thymidylate synthase (TS) for de novo synthesis and thymidylate kinase (TMK), which is required for both pathways. Our study population consisted of 211 premenopausal women with node-negative tumors. SPF was assessed prospectively by flow cytometry, whereas enzyme activities were measured retrospectively in cytosols using radioenzymatic methods. Among the enzymes analyzed, only TK demonstrated a strong correlation with SPF (r(s) = 0.59). In univariate analysis, high SPF and high levels of TK were associated with increased risk of developing distant recurrences (p < 0.001). Correlations with other prognostic factors (histological grade, steroid receptors, DNA ploidy status, urokinase plasminogen activator and plasminogen activator inhibitor type 1) confirmed a parallel association of SPF and TK with the most aggressive tumors. In contrast, TS and TMK were not associated with prognosis. After adjustment for SPF, the risk of relapse increased significantly with TK values. Subgroup analysis showed that additional information was provided by TK in the tumors with low SPF. When urokinase plasminogen activator (uPA) was a candidate variable in multivariate analysis, TK remained significant. Combined with SPF and uPA, TK could be useful to define premenopausal node-negative patients with rapidly proliferating tumors at a high risk of metastatic disease. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241312     DOI: 10.1002/1097-0215(20010120)95:1<56::aid-ijc1010>3.0.co;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Authors:  Chafika Mazouni; Frédéric Fina; Sylvie Romain; Pascal Bonnier; L'houcine Ouafik; Pierre-Marie Martin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

2.  Epstein-Barr virus as a marker of biological aggressiveness in breast cancer.

Authors:  C Mazouni; F Fina; S Romain; L Ouafik; P Bonnier; J-M Brandone; P-M Martin
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

3.  Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.

Authors:  Costanza Paoletti; William E Barlow; Erin F Cobain; Mattias Bergqvist; Rita S Mehta; Julie R Gralow; Gabriel N Hortobagyi; Kathy S Albain; Lajos Pusztai; Priyanka Sharma; Andrew K Godwin; Alastair M Thompson; Daniel F Hayes; James M Rae
Journal:  Clin Cancer Res       Date:  2021-09-14       Impact factor: 12.531

4.  Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.

Authors:  Kyle G Potts; Chad R Irwin; Nicole A Favis; Desmond B Pink; Krista M Vincent; John D Lewis; Ronald B Moore; Mary M Hitt; David H Evans
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.